Merck KGaA agrees to buy Rapid Micro Biosystems
Rapid Micro Biosystems, a Lexington, Massachusetts maker of automated microbial quality control systems, agreed to be acquired by Merck KGaA; terms were not disclosed.
- Target
- Rapid Micro Biosystems
- Buyer
- Merck KGaA, Darmstadt, Germany
- Seller
- Kleiner Perkins
Rapid Micro Biosystems (Nasdaq: RPID) has signed a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany, under which Merck KGaA will acquire all outstanding shares of the company. The agreement was announced on November 16, 2026, alongside the company's third-quarter 2026 results.
Rapid Micro Biosystems is headquartered in Lexington, Massachusetts, with U.S. manufacturing in Lowell and locations in Switzerland, Germany and the Netherlands. Its flagship Growth Direct system automates manual microbial quality control testing used in pharmaceutical and biologics manufacturing. The company reported third-quarter 2026 revenue of $9.5 million, up 22% year over year.
CEO Rob Spignesi said joining the Life Science business of Merck KGaA would significantly expand the reach of the Growth Direct platform and accelerate its adoption. Rapid Micro Biosystems said it will not host a call on the quarter and is withdrawing its full-year 2026 guidance.
Background
- Business
- Life sciences technology company providing automation for microbial quality control testing in pharmaceutical manufacturing
- Deal type
- Exit
- Headquarters
- Lexington, Massachusetts
Sources
- GlobeNewswire via Quiver QuantitativeNov 16, 2026
- marketscreener.comNov 15, 2026
Written by Buyout Desk from the sources above. Spotted an error? Email corrections@buyoutdesk.com.
Follow coverage. Copy a feed link into your feed reader.